MiNK Therapeutics

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

MiNK Therapeutics
Dec 20, 2024, 22:35 | Blog
Jennifer S. Buell: Transforming cancer care through innovation in immuno-oncology
Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, posted the following on…
Dec 14, 2024, 15:49 | Career
FairJourney Biologics has appointed Marc van Dijk as the new Chief Scientific Officer of Antibody Discovery and Engineering
FairJourney Biologics recently appointed Marc van Dijk as the new Chief Scientific Officer of Antibody…
Dec 4, 2024, 09:54 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024
Starting on August 26, in honor of Women’s Equality Day in the United States, which…
Nov 14, 2024, 00:24 | Blog
Jennifer Buell: Thrilled to share MiNK Therapeutics' groundbreaking work at SITC 2024
Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared a post on LinkedIn…
Nov 8, 2024, 12:37 | Positive
Jennifer Buell: Pioneering Leadership in Biotechnology
Dr. Jennifer Buell is a prominent figure in the biotechnology industry, currently serving as the…
Oct 25, 2024, 16:34 | Insight
Three decades of pioneering in Immune Oncology - Agenus
Agenus Inc. is a biopharmaceutical company and a prominent leader in the field of immuno-oncology,…
Oct 9, 2024, 15:29 | Blog
A collaboration between MiNK Therapeutics and Autonomous Therapeutics
MiNK Therapeutics and Autonomous Therapeutics have announced a collaboration aimed at developing innovative therapies for…
Jul 8, 2024, 12:29 | Drugs
Jennifer Buell: NCI Announces Availability of Botensilimab for Clinical Development
Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics, shared on X: “NCI Announces…
May 17, 2024, 04:19 | Blog
MiNK Therapeutics' Q1 report
MiNK Therapeutics shared on LinkedIn: . "This quarter we made significant strides across our iNKT…
Apr 5, 2024, 09:43 | Blog
Jennifer Buell: I’m matching all gifts from tonight through the end of April 5th.
Jennifer Buell, the President and Chief Executive Officer of MiNK Therapeutics, shared on Facebook: "Let’s…
Mar 24, 2024, 13:10 | Blog
MiNK Therapeutics announced results for the fourth quarter and year-end of 2023
MiNK Therapeutics shared on their LinkedIn page: "Today MiNK announced results for the fourth quarter…
Mar 7, 2024, 01:57 | Blog
Jennifer Buell: Tune-in: MiNK Therapeutics to unveil pioneering data on the novel armored FAP-CAR-INKT (MiNK-215) at AACR Meeting, April 8
Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared a post by MiNK Therapeutics…
Feb 14, 2024, 14:59 | Blog
Yelena Janjigian is leading the investigator-initiated trial of the First Novel Combination of MiNK's Allogeneic Cell Therapy with Agenus' BOT/BAL
Today MiNK Therapeutics released an announcement of the First Refractory Gastric Cancer Patient Dosed in…
Feb 6, 2024, 14:34 | Blog
Potential of iNKT cells to combat resistance to immune checkpoint inhibitors - MiNK Therapeutics
Quoting MiNK Therapeutics on LinkedIn: "New publication in Oncogene spotlights a compelling case study of…
Oct 3, 2023, 16:52 | Blog,Insight
Jennifer Buell: MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023 - Bloomberg.
Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared a post by Bloomberg…
All: 15 Posts: 1 - 100
Special Coverage